Category: Stock News
-
uniQure’s FDA Update on AMT-130: What’s Next for QURE Stock?
uniQure (QURE) faces FDA hurdle for AMT-130 approval. Discover the implications for QURE stock, key takeaways, and future outlook in our analysis.
-
Kelly Services Recognized as a Leader by Everest Group in 2025
Kelly named a Leader and Star Performer on Everest Group’s 2025 US Contingent Staffing PEAK Matrix. The recognition highlights Kelly’s excellence in outcome-based managed services, tech investments, and growth in semiconductors and renewable energy.
-
uniQure Secures $175M Debt Facility: Is QURE Stock a Buy Now?
uniQure (QURE) refinances $50M debt, secures $125M funding. Is QURE stock a buy? Find out about uniQure’s financial strategy and AMT-130 prospects.
-
LYRA Stock Soars: Phase 3 Trial Success for LYR-210 CRS Treatment
New Phase 3 data reveals significant CRS symptom improvement with LYR-210. Key endpoints met with p=0.0078. Potential FDA submission path emerging. See full results for LYRA stock.